The latest price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL) was reported by Guggenheim on April 10, 2026. The analyst firm set a price target for $10.00 expecting ZNTL to rise to within 12 months (a possible 141.55% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) was provided by Guggenheim, and Zentalis Pharmaceuticals maintained their buy rating.

The last upgrade for Zentalis Pharmaceuticals Inc happened on August 12, 2024 when Wedbush raised their price target to $4. Wedbush previously had an underperform for Zentalis Pharmaceuticals Inc.

The last downgrade for Zentalis Pharmaceuticals Inc happened on June 20, 2024 when UBS changed their price target from $28 to $5 for Zentalis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharmaceuticals was filed on April 10, 2026 so you should expect the next rating to be made available sometime around April 10, 2027.

While ratings are subjective and will change, the latest Zentalis Pharmaceuticals (ZNTL) rating was a maintained with a price target of $6.00 to $10.00. The current price Zentalis Pharmaceuticals (ZNTL) is trading at is $4.14, which is out of the analyst’s predicted range.